Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Medtronic
Colorcon
AstraZeneca
Express Scripts

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Claims for Patent: 10,322,162

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,322,162
Title:Methods and pharmaceutical compositions for the treatment of ischemic conditions
Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of ischemic conditions. In particular, the present invention relates to a method of treating an ischemic condition in a subject in need thereof comprising administering the subject with a polypeptide comprising an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino acid residue at position 186 to the amino acid residue at position 406 in SEQ ID NO: 1.
Inventor(s): Germain; Stephane (Paris, FR), Berdeaux; Alain (Creteil, FR), Tissier; Renaud (Creteil, FR), Ghaleh-Marzban; Bijan (Creteil, FR), Monnot; Catherine (Paris, FR), Galaup; Ariane (Paris, FR)
Assignee: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) COLLEGE DE FRANCE (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Creteil, FR) UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE (Creteil, FR) ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP) (Paris, FR) ECOLE NATIONALE VETERINAIRE D\'ALFORT (ENVA) (Maisons-Alfort, FR)
Application Number:15/541,422
Patent Claims:1. A method of treating an ischemic organ or tissue in a subject in need thereof comprising administering to the subject a synthetic ANGPTL4 polypeptide fragment comprising an amino acid sequence as set forth from position 186 to position 406 in SEQ ID NO:1, provided that said polypeptide is not SEQ ID NO:1, wherein the synthetic ANGPTL4 polypeptide fragment is administered in an amount sufficient to preserve vascular endothelial cell barrier integrity in the ischemic organ or tissue.

2. The method of claim 1 wherein the ischemic organ or tissue is the result of renal ischemia, retinal ischemia, brain ischemia or myocardial ischemia.

3. The method of claim 1 wherein the subject is suffering from at least one condition is-selected from the group consisting of coronary artery bypass graft surgery, global cerebral ischemia due to cardiac arrest, focal cerebral infarction, cerebral hemorrhage, hemorrhage infarction, hypertensive hemorrhage, hemorrhage due to rupture of intracranial vascular abnormalities, subarachnoid hemorrhage due to rupture of intracranial arterial aneurysms, hypertensive encephalopathy, carotid stenosis or occlusion leading to cerebral ischemia, cardiogenic thromboembolism, stroke, spinal stroke and spinal cord injury, vasculitis, macular degeneration, myocardial infarction, cardiac ischemia and supraventricular tachyarrhythmia.

4. The method of claim 1 wherein the synthetic ANGPTL4 polypeptide fragment is administered sequentially or concomitantly with a standard method selected from the group consisting of reperfusion of the ischemic organ by angioplasty, percutaneous coronary intervention, thrombolysis and coronary surgery.

5. The method of claim 1 wherein the synthetic ANGPTL4 polypeptide fragment is administered sequentially or concomitantly with a thrombolyic agent selected from the group consisting of reteplase, alteplase, urokinase, prourokinase, anisoylated purified streptokinase activator complex, and streptokinase.

6. The method of claim 1 wherein the synthetic ANGPTL4 polypeptide fragment is fused to a Fc domain of an immunoglobulin.

7. A method of treating acute myocardial infarction in a patient in need thereof comprising the steps of i) restoring blood supply in cardiac ischemic tissue, and ii) preserving vascular endothelial cell bather integrity of said cardiac ischemic tissue by administering to said patient a therapeutically effective amount of a synthetic ANGPTL4 polypeptide fragment to reduce infarct size, hemorrhage, and no-reflow, where steps i) and ii) are performed sequentially or concomitantly and wherein the synthetic ANGPTL4 polypeptide fragment comprises an amino acid sequence as set forth from position 186 to position 406 in SEQ ID NO:1, provided that said polypeptide is not SEQ ID NO:1.

8. A method of treating at least one ischemic organ or tissue in a patient in need thereof, comprising the steps of restoring blood supply in the at least one ischemic organ or tissue selected from the group consisting of heart, kidney, retina and brain; and administering to said patient a therapeutically effective amount of a synthetic ANGPTL4 polypeptide fragment having an amino acid sequence as set forth in SEQ ID NO:1 from position 186 to position 406, provided that said polypeptide is not SEQ ID NO:1; wherein said restoring and administering steps are performed sequentially or concomitantly, and wherein vascular endothelial cell barrier integrity of the at least one ischemic organ or tissue is preserved.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
15305008Jan 6, 2015
PCT Information
PCT FiledJanuary 06, 2016PCT Application Number:PCT/EP2016/050108
PCT Publication Date:July 14, 2016PCT Publication Number:WO2016/110498

Details for Patent 10,322,162

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech ACTIVASE alteplase VIAL; SINGLE-USE 103172 001 1987-11-13   Start Trial INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) COLLEGE DE FRANCE (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Creteil, FR) UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE (Creteil, FR) ASSI 2035-01-06 RX search
Genentech ACTIVASE alteplase VIAL; SINGLE-USE 103172 002 1987-11-13   Start Trial INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) COLLEGE DE FRANCE (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Creteil, FR) UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE (Creteil, FR) ASSI 2035-01-06 RX search
Genentech CATHFLO ACTIVASE alteplase VIAL 103172 003 1987-11-13   Start Trial INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) COLLEGE DE FRANCE (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Creteil, FR) UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE (Creteil, FR) ASSI 2035-01-06 RX search
Ekr Therap RETAVASE reteplase VIAL 103786 001 1998-05-06   Start Trial INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) COLLEGE DE FRANCE (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Creteil, FR) UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE (Creteil, FR) ASSI 2035-01-06 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Express Scripts
McKesson
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.